Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Estudo de Viabilidade DPP de Amamentação - eMOMS 2.0

26 de outubro de 2026 atualizado por: Lisette Jacobson, University of Kansas Medical Center

Estudo de Viabilidade do Programa de Prevenção de Diabetes de Amamentação - Monitoramento Eletrônico da Agenda da Mamãe 2.0

The purpose of this study is to investigate the impact of a comprehensive intervention that combines breastfeeding support with a diabetes prevention-based program (DPP) on postpartum weight retention and lactation duration among women with pre-pregnancy overweight or obesity. This intervention, named eMOMS, is delivered by a certified health coach via a mobile health (mHealth) application.

Visão geral do estudo

Descrição detalhada

This study is a randomized controlled trial designed to determine the feasibility and efficacy of a combined breastfeeding, diabetes prevention-based program (DPP) in a cohort of overweight or obese women to be followed during pregnancy through 3 months postpartum. The trial will have two study arms: DPP + breastfeeding (Tx1) and Usual Care (Tx2).

Aim 1: Measure weight loss and duration of lactation through 3 months postpartum among target population. To accomplish this, we will measure pre-pregnancy weight, weight at study entry, weight immediately prior to and after delivery, and weight at specific postpartum time points. Lactation and infant feeding practices will be measured at similar postpartum time points. Aim 2: Quantify interest in use of the DPP-lactation mobile health (mHealth) application among target population. To accomplish this, we will: (1) measure research engagement including rates of screening and recruitment among users, especially rural and racially/ethnically diverse women; and (2) evaluate intervention uptake, delivery, and adherence via tracking/measuring use of the mHealth app.

Tipo de estudo

Intervencional

Inscrição (Real)

43

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Kansas
      • Wichita, Kansas, Estados Unidos, 67218
        • Via Christi Maternal Fetal Medicine Clinic

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Fêmea

Descrição

Inclusion Criteria:

  • Pregnant
  • In second trimester or early third trimester
  • BMI >/= 25 and < 35
  • At least 18 years old or older
  • Able to read and understand English
  • Able to learn and use a video platform

Exclusion Criteria:

  • Complications related to pregnancy that require emergency care
  • Thyroid disease
  • Multiple gestation
  • Substance abuse within last 3 years
  • Assisted reproductive technology (ART)-related pregnancy
  • Current smoker
  • Prior bariatric surgery
  • In weight-loss program within 3 months of conception
  • BMI >/= 35
  • Unable to attend intervention/ follow-up visits
  • Unwilling to self-monitor data collection
  • Unable to complete intervention
  • Presence of any condition that limits walking
  • Presence of any condition that limits following diet recommendations
  • Pregnancies complicated with fetuses diagnosed with lethal malformations/conditions

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Comparador Ativo: DPP + Breastfeeding (Tx1)

Patients randomized to Tx1 will receive education in the Diabetes Prevention Program (DPP) and intensive breastfeeding education and support. Ante- and postpartum education includes access to the mHealth app and individualized 1-on-1 health coaching. Phase I is delivered antepartum and includes: four (4) 1-hour DPP-based educational sessions and six (6) 20-minute educational videos on lactation. Phase II is delivered postpartum and includes: in-hospital lactation support and two (2) 1-hour DPP-based educational sessions. Participants will continue to receive individualized 1-on-1 health coaching through 3 months postpartum.

The intervention will be administered by professionally trained, certified health coaches. Phase I consists of four 1-hour DPP-based sessions to be completed during pregnancy. Each session will be pre-recorded and archived on a secure, private mHealth application. Participants will be asked to complete each session on their own time. A health coach will follow up weekly via phone to check on progress and will work with the participant 1-on-1, if needed. Phase I will be completed by week 36 of pregnancy. Prior to delivery, participants are invited to a virtual focus group about their experiences.

Phase II consists of two 1-hour DPP-based sessions to be completed after delivery. Each session will be pre-recorded and archived on the same mHealth application. Participants will begin Phase II within 1 week of delivery with the same health coach. Phase II will be completed by week 12 postpartum. Upon completion, participants are invited to a virtual focus group about their experiences.

Phase I also consists of six (6) breastfeeding videos that are pre-recorded into 15-20 minute sessions and will be available on the mHealth application. Participants will have access to the first 2 sessions by week 28 of pregnancy and need to complete the remaining 4 sessions by week 36 of pregnancy. Each session is taught by an International Board Certified Lactation Consultant (IBCLC).

Participants will receive 1-on-1 lactation support by the same DPP health coach. The health coach is a professionally trained Certified Breastfeeding Specialist (CBS). She will assist participants with any questions related to lactation. If the health coach is unable to help with a specific issue, she will contact the IBCLC-of-record, who will provide assistance to the health coach only. If the health coach or IBCLC deems additional care necessary, the participant will be referred to their primary care physician. The IBCLC will not have direct contact with the study participants.

Participants will receive regular prenatal care provided by their physician. At delivery, all participants will receive some type of lactation support in the hospital.

Comparador de Placebo: Usual Care

Usual care is described as obstetrical care that pregnant women with normal BMI receive and that is provided by their provider. There will not be any antepartum education or 1-on-1 health coaching. Postpartum education will only include usual care in-hospital lactation support. There will not be any other education nor 1-on-1 support.

Participants will receive regular prenatal care provided by their physician. At delivery, all participants will receive some type of lactation support in the hospital.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Change in Weight
Prazo: At baseline and at delivery through 3 months postpartum

The study team measured maternal weight at baseline, at delivery, and at 3 months postpartum to allow for meaningful comparisons of weight change among study arms.

At baseline and at delivery through 3 months postpartum
Maternal Weight
Prazo: At baseline and at delivery through 3 months postpartum

The study team measured maternal weight at baseline, at delivery, and at 3 months postpartum to allow for meaningful comparisons of weight change among study arms.

At baseline and at delivery through 3 months postpartum
Duration of Breastfeeding and Supplementation
Prazo: At day 3, week 6, and 3 months postpartum.

The study team measured duration of breastfeeding and supplementation at day 3 postpartum and at specific timepoints through 3 months postpartum. Breastfeeding is defined as the feeding of human milk. The definition of "Exclusive Breastfeeding" is aligned with the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) and is as follows: the infant is fed only human milk and no other foods or fluids, not even water, except for oral rehydration solutions or drops/syrups of vitamins, minerals, or medicines. "Any Breastfeeding" is defined as the feeding of human milk supplemented with formula, water, etc. "Formula Only" is defined as the feeding of formula exclusively and no human milk.

At day 3, week 6, and 3 months postpartum.

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Enrollment
Prazo: This will occur between day 1 of the first participant screened to the study participant being randomized to one of two study arms.

To assess recruitment and enrollment rates, the study team tracked the number of potential participants contacted/screened versus the number of participants who were eligible to enroll and the number of participants who consented to enroll in the study.

This will occur between day 1 of the first participant screened to the study participant being randomized to one of two study arms.
mHealth Application Engagement
Prazo: At 3 months postpartum.

To assess intervention uptake, the study team tracked the number of calls engaging with the mobile health app and with the health coach.

At 3 months postpartum.
mHealth Application Engagement (2)
Prazo: At 3 months postpartum.

To assess intervention uptake, the study team tracked the amount of time spent engaging with the mobile health app and with the health coach.

At 3 months postpartum.
mHealth Application Usage
Prazo: At 3 months postpartum.

To assess intervention usage, the study team tracked logged tasks into the mobile health app.

At 3 months postpartum.

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Lisette Jacobson, PhD, MPA, MA, University of Kansas Medical Center

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

30 de abril de 2024

Conclusão Primária (Real)

31 de agosto de 2025

Conclusão do estudo (Real)

31 de agosto de 2025

Datas de inscrição no estudo

Enviado pela primeira vez

4 de abril de 2024

Enviado pela primeira vez que atendeu aos critérios de CQ

15 de abril de 2024

Primeira postagem (Real)

18 de abril de 2024

Atualizações de registro de estudo

Última Atualização Postada (Real)

17 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

26 de outubro de 2026

Última verificação

1 de outubro de 2026

Mais Informações

Termos relacionados a este estudo

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever